Keywords: Parkinson's Disease, Neurodegeneration
Motivation: Parkinsonism neurodegeneration is driven by diverse proteinopathies. The brain glymphatic system associates with neurodegenerative disorders characterized by neurotoxic protein aggregation.
Goal(s): To find more neuroimaging biomarkers and assist the target treatment of parkinsonism.
Approach: We calculated ChP volume, ratio and ALPS index to reflect the brain glymphatic function to grasp the change of brain glymphatic function in early PD, PSP and MSA.
Results: The ALPS was lowest in PSP while ChP showed a greater dispersion. When combining PD and MSA groups into α-synucleinopathies group and regarding PSP as tauopathy group, ALPS in tauopathy group was higher with an increasing ChP volume and ratio.
Impact: Impaired glymphatic function might be a pathophysiology marker of neurodegeneration disorders. Although the dispersion of ChP implies that this may not be a stabilizing factor, impaired glymphatic hydrodynamic function also support for glymphatic dysfunction in the proteopathy of parkinsonism.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords